HopeStage
Back to all studies
CompletedNCT02564588

Dasotraline for Adults With Binge Eating Disorder

About this title

Dasotraline Binge Eating Disorder Study

Read the official source — NCT02564588

Researchers compared Dasotraline and placebo, tracking side effects to assess safety and tolerability in adults with binge eating.

Medication studyAges 18–55United StatesEating disorders
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Dasotraline and placebo, tracking side effects to assess safety and tolerability in adults with binge eating.

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
Beverly Hills and 42 more locationsSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2015
Recruitment status
Completed
Enrollment listed in the registry
319
Sponsor
Sumitomo Pharma America, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT02564588
Official title
Show the full official title

A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Beverly Hills · Encino · Garden Grove

39 more locations
  • Newport Beach
  • San Diego
  • Santa Ana
  • Denver
  • Jacksonville
  • North Miami
  • Orlando
  • South Miami
  • Alpharetta
  • Atlanta
  • Libertyville
  • Indianapolis
  • Wichita
  • Belmont
  • Watertown
  • Saint Charles
  • Princeton
  • Mount Kisco
  • Raleigh
  • Akron
  • Cincinnati
  • Dayton
  • Mason
  • Middleburg Heights
  • Oklahoma City
  • Medford
  • Portland
  • Salem
  • Allentown
  • Anderson
  • Greer
  • Dallas
  • Houston
  • Plano
  • Murray
  • Ogden
  • Woodstock
  • Herndon
  • Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Dasotraline and placebo, tracking side effects to assess safety and tolerability in adults with binge eating.

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Dasotraline and Placebo.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies